SCHEMBL3516702

SCHEMBL3516702

COC(=O)c1c(OC)cc(Br)c2nccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
PRKDC P78527 1/20 0.38
GRM4 Q14833 1/20 0.37
APAF1 O14727 1/20 0.37
TDP2 O95551 1/20 0.37
NSD2 O96028 1/20 0.37
CASP3 P42574 1/20 0.37
PPP1CA P62136 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
APP P05067 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ERN1 O75460 1/20 0.36
KDM1A O60341 1/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17041958 0.77 BRD4 (0.38) LCKFYNMEN1KMT2ATSHR
SCHEMBL3758964 0.76 MEN1 (0.54) MEN1KMT2AKDM4ETSHRHTT
SCHEMBL3521595 0.76 MAPT (0.37) MEN1KMT2AALDH1A1TSHRHTT
SCHEMBL27402555 0.73 ALOX15 (0.44) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL31210536 0.73 KMT2A (0.39) LCKFYNPRKDCMEN1KMT2A
SCHEMBL21616730 0.72 ERN1 (0.46) LCKFYNERN1ALDH1A1KDM4E
SCHEMBL30676961 0.71 LCK (0.42) LCKFYNMEN1KMT2AALDH1A1
SCHEMBL19892909 0.70 KDM4E (0.46) MEN1KMT2AALDH1A1KDM4ETSHR
SCHEMBL31214362 0.69 CA12 (0.40) GRM4APAF1TDP2NSD2CASP3
SCHEMBL26670660 0.69 POLB (0.41) MEN1KMT2AALDH1A1KDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 LCK 4579/4885FYN 4823/4885PRKDC 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.